Treatment of beta-thujaplicin counteracts di(2-ethylhexyl)phthalate (DEHP)-exposed vascular smooth muscle activation, inflammation and atherosclerosis progression

doi:10.1016/j.yrtph.2017.12.021

CNU IR > Pharmacy and Science > Dept. of Pharmacy > Periodical Articles > Item 310902800/32153

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32153

Title:	Treatment of beta-thujaplicin counteracts di(2-ethylhexyl)phthalate (DEHP)-exposed vascular smooth muscle activation, inflammation and atherosclerosis progression
Authors:	Shih, Mei Fen Pan, Kuang-Hung Liu, Chia-Chyuan Shen, Chia-Rui Cherng, Jong Yuh
Contributors:	Chia Nan Univ Pharm & Sci, Dept Pharm Natl Chung Cheng Univ, Dept Chem & Biochem Chia Nan Univ Pharm & Sci, Dept & Inst Cosmet Sci Chang Gung Univ, Dept Med Biotechnol & Lab Sci
Keywords:	13-thujaplicin DEHP Plasticizer E-selectin ICAM-1 VCAM-1 MMP-2 MMP-9
Date:	2018-02
Issue Date:	2019-11-15 15:42:58 (UTC+8)
Publisher:	ACADEMIC PRESS INC ELSEVIER SCIENCE
Abstract:	The initiation of atherosclerosis involves up-regulation of molecules such as E-selectin, VCAM-1, and ICAM-1. The progression of atherosclerosis is linked to proliferation and migration of vascular smooth muscle cell via MMP-2 and MMP-9 activities. However, the etiology of atherosclerosis concerning plasticizers is unknown. We evaluated beta-thujaplicin in preventing the development of atherosclerosis in a model induced by pro-inflammatory cytokines. Moreover, we established a new atherosclerosis model in vascular smooth muscle cells (VSMC) exposed to a common contact plasticizer, di(2-ethylhexyl)phthalate (DEHP). SEVC4-10 endothelial cells were treated with 50% RAW conditioned medium and A7r5 VSMC was treated with the plasticizer, with/without beta-thujaplicin (4 or 12 mu M). Production of E-selectin, ICAM-1, and VCAM-1 in SEVC4-10 cells as well as MMP-2/MMP-9 (both expression and activity) in VSMC were monitored. Results showed that the conditioned medium induced E-selectin and ICAM were significantly prevented by beta-thujaplicin. However, inhibition on the production of VCAM by beta-thujaplicin was only seen in a concentration of 12 mu M. Both concentrations of beta-thujaplicin also significantly prevented DEHP-induced MMP-2 and MMP-9 expression and activities. Evidence uncovers that beta-thujaplicin has additional factors in amelioration of atherosclerosis and corroborates that beta-thujaplicin is a strong candidate in preventing the initiation and progression of atherosclerosis.
???metadata.dc.relation.uri???:	http://dx.doi.org/10.1016/j.yrtph.2017.12.021
Relation:	Journal of Environmental Management, v.92, pp.333-337
Appears in Collections:	[Dept. of Pharmacy] Periodical Articles [Dept. of Cosmetic Science and institute of cosmetic science] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1296	View/Open

Loading...